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http://dx.doi.org/10.1016/j.ccr.2012.06.013SUMMARYWe show that R-Ras, a small GTPase of the Ras family, is essential for the establishment ofmature, functional
blood vessels in tumors. The genetic disruption of R-Ras severely impaired the maturation processes of
tumor vessels in mice. Conversely, the gain of function of R-Ras improved vessel structure and blood perfu-
sion and blocked plasma leakage by enhanced endothelial barrier function and pericyte association with
nascent blood vessels. Thus, R-Ras promotes normalization of the tumor vasculature. These findings identify
R-Ras as a critical regulator of vessel integrity and function during tumor vascularization.INTRODUCTION
Tumor vasculature is structurally and functionally abnormal
(Jain, 2005). These vessels are highly permeable, tortuous,
dilated, and saccular, and are poorly covered by mural cells
(pericytes). These properties, which are mainly attributed to the
impaired maturation process of the tumor vessels, cause inade-
quate blood circulation and poor oxygenation of the tumors.
Although this could slow down tumor growth, it also reduces
the sensitivity of the tumors to ionizing radiation and impedes
the delivery of chemotherapeutic agents, allowing the tumors
to become resistant to cytotoxic therapies (Jain, 2005). The
plasma leakage from tumor vessels elevates the interstitial fluid
pressure within the tumor and significantly reduces the diffusion
of therapeutic agents (Jain, 2005). Cerebral edema caused by
leaky vessels is a serious complication in brain cancer. The
vessel leakiness also allows invasive tumor cells to penetrate
into circulation and facilitates distant metastasis (Weis et al.,
2004). Therefore, the functionality of tumor blood vessels criti-Significance
Newly formed blood vessels in tumors fail to mature into fully fu
vironment. The functional impairment of these vessels hamper
therapies. Excessive vessel permeability associated with tumo
in brain cancer patients. Therefore, the ability to control vesse
tunity. This study revealed a key role for R-Ras in promoting tum
role, R-Ras expressed in endothelial cells and in pericytes bot
suggests R-Ras as a potential target for controlling blood circcally impacts tumor progression and tumors responses to ther-
apeutic regimens (Bergers and Hanahan, 2008; Carmeliet and
Jain, 2011b).
Previous studies suggested that vascular endothelial growth
factor (VEGF)-targeted cancer therapies lead not only to inhibi-
tion of tumor angiogenesis but also to transient maturation and
normalization of tumor vasculature, thereby improving the
delivery of chemotherapeutic compounds, enhancing the effi-
cacy of chemotherapy (Carmeliet and Jain, 2011b). However,
recent reports have demonstrated that VEGF-targeted therapies
also result in increased tumor invasiveness and distant metas-
tasis in mice, potentially explaining the lack of lasting clinical
responses to the current antiangiogenic treatments (Ebos
et al., 2009; Pa`ez-Ribes et al., 2009). These studies highlight
the importance of a better understanding of the biology of
tumor angiogenesis and its implications in tumor malignancy
and therapies. The molecular and cellular mechanisms that
govern vessel maturation, especially in tumor vasculature,
remain elusive at present. The currently held view is that thenctional vessels due to the chronically angiogenic microen-
s drug delivery, thereby diminishing the efficacy of antitumor
rs also causes clinical complications such as cerebral edema
l maturity in tumors provides a potential therapeutic oppor-
or vessel maturation and normalization. Consistent with this
h contribute individually to the vessel regulation. This study
ulation and vascular permeability in solid tumors.
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Cancer Cell
Normalization of Tumor Vasculature by R-Rasprocesses of vessel formation and maturation are regulated by
the balance between pro-angiogenic and antiangiogenic signals
(Carmeliet and Jain, 2011a; Darland and D’Amore, 1999).
Previously, we identified an antiangiogenic activity of a small
GTPase, R-Ras (Komatsu and Ruoslahti, 2005). R-Ras is
strongly expressed in fully differentiated, quiescent vascular
smooth muscle cells and endothelial cells of normal adult vascu-
lature. Unlike the prototypic Ras oncoproteins such as K-Ras
and H-Ras, R-Ras inhibits vascular cell proliferation and inva-
sion, and promotes vascular quiescence via yet unidentified
pathways. Challenging R-Ras knockout mice with arterial injury
or tumor implantation induced exaggerated neointimal thick-
ening and increased angiogenesis in the tumors. Thus, R-Ras
signaling primarily affects vessel remodeling and regeneration
by counterbalancing the vessel activation. However, the effect
of R-Ras is distinct from the effect of classic antiangiogenic
agents: R-Ras does not induce endothelial cell death. Instead,
it induces quiescence of endothelial cells while supporting their
survival—activities that promote vessel maturation. R-Ras
expression level correlates with the maturation status of the
vessels, suggesting a role of R-Ras in the cellular processes
essential for the vessel maturation. Little expression of R-Ras
was detected in the developmentally growing or pathologically
regenerating vessels such as angiogenic vessels in the tumor
and hyperplastic neointimal lesion in acute arterial injury in
mice. In comparison, abundant expression was found in mature
functional vessels of normal adult tissues and in dormant arterial
lesions (Komatsu and Ruoslahti, 2005). Based on these observa-
tions, we hypothesized that R-Ras promotes maturation of
regenerating adult vasculature and that chronically reduced
R-Ras expression in tumor vessels causes the immaturity and
poor functionality of these vessels. In the present study, we
tested this hypothesis by analyzing the effect of R-Ras defi-
ciency or upregulation on the structural and functional integrity
of tumor vessels.
RESULTS
R-Ras Deficiency Severely Impairs Maturation Process
of Tumor Blood Vessels
Close interaction between nascent endothelium and pericytes is
crucial for vessel maturation, and tumor vasculature is charac-
terized by insufficient pericyte association (Jain, 2003). Using
a computer-assisted three-dimensional (3D) image reconstruc-
tion (MoviesS1AandS1Bavailable online), we founda significant
reduction of the direct physical contact between pericytes and
the endothelium of blood vessels developed in subcutaneous
tumor implants in R-Ras knockout mice (Figures 1A and 1B).
A similar 3D analysis of these vessels revealed severely impaired
coverage by collagen IV, a major constituent of normal endothe-
lial basementmembrane (Figures 1C and 1D). Reflecting aweak-
ened pericyte and basement membrane support, these vessels
were often found to be more dilated or saccular, and their endo-
thelium exhibited more severe deformations compared with
that of the wild-type tumor vessels (Figures 1E–1H). Our analysis
suggests that the vessel deformity caused by the R-Ras defi-
ciency is also linked to the abnormality in the VE-cadherin-
mediated vessel stabilization. VE-cadherin is essential for the
structural integrity of blood vessels, and its genetic disruption236 Cancer Cell 22, 235–249, August 14, 2012 ª2012 Elsevier Inc.leads to leaky vessels, hemorrhaging, and prenatal lethality
(Crosby et al., 2005; Gory-Faure´ et al., 1999). The intensity of
VE-cadherin immunostaining was diminished in the R-Ras-defi-
cient vessels (Figure 1E), suggesting that the endothelial adhe-
rens junctions of the tumor vessels are disrupted or unstable in
the absence of R-Ras. Taken together, these results indicate
an important role of R-Ras in establishing close endothelial
cell-pericyte interaction, basement membrane formation, and
endothelial integrity, which are essential for the maturation of
blood vessels. Consequently, the R-Ras deficiency greatly exac-
erbates the tumor-associated immature and abnormal charac-
teristics of blood vessels.
R-Ras Dictates Blood Vessel Phenotype in Tumors
To further evaluate the ability of R-Ras to regulate blood vessel
maturation in the tumor microenvironment, we determined the
expression status of VEGF receptor 2 (VEGFR2), a molecular
marker highly expressed by the endothelium of growing, imma-
ture vessels (Heidenreich et al., 2000; Kappel et al., 1999).
VEGFR2 and R-Ras show opposite temporal expression
patterns during mouse development: developing prenatal
vessels are VEGFR2high, R-Rasundetected, whereas quiescent
adult vessels are VEGFR2low, R-Rashigh (Heidenreich et al.,
2000; Kappel et al., 1999; Komatsu and Ruoslahti, 2005). In the
present study, using B16F10 melanoma implants, tumor vascu-
lature in wild-type control mice contained a mixed population of
vessels expressing high to low levels of VEGFR2, with the
majority of the vessel population being VEGFR2high (Figures 2A
and 2B). This result reflects the fact that tumor vessels are
generally immature, while containing a small subpopulation of
relatively mature vessels formed by VEGFR2low endothelium
(Heidenreich et al., 2000; Mancuso et al., 2006) (Figure 2B).
These relatively established vessels are a minority, but function-
ally important, because they can deliver blood and drugs more
efficiently to the tumor than immature vessels and are resistant
to antiangiogenic treatment by VEGF blockade (Helfrich et al.,
2010; Jain, 2005; Mancuso et al., 2006). In R-Ras knockout
mice, this VEGFR2low subpopulation was absent from the tumor
vasculature. Instead, the vessel population has largely shifted to
VEGFR2high, immature phenotype (Figure 2B) demonstrating
that R-Ras is required for maturation of tumor blood vessels.
Analysis of the angiogenic ECmarker, av integrin subunit expres-
sion (Stupack and Cheresh, 2002), also demonstrated a major
shift of vessel populations to a highly angiogenic av integrin
high
phenotype in the R-Ras-deficient vasculature (Figure 2C), again
indicating a state of unattenuated vessel activation, consistent
with their failure to mature. Similar results were obtained in
subcutaneous implants of Lewis lung carcinoma (LLC) tumors
(Figure S1).
Malfunctions of Tumor Vessels Are Augmented by the
R-Ras Deficiency
The defects in pericyte support, aberrant basement membrane,
and structural deformity of blood vessels are associated with
poor functionality of the vasculature (Jain, 2005). Consistent
with this notion, tumors in the R-Ras knockout mice showed
increased vessel permeability and plasma leakage, as indicated
by elevated levels of provisional matrix (fibrinogen/fibrin) deposi-
tion around the tumor vessels (Figures 3A and 3B). Further
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Figure 1. Pronounced Structural Abnormalities of Tumor Vessels Caused by the R-Ras Deficiency
(A) Endothelium and associated pericytes were visualized by CD31 (red) and NG2 (green) immunofluorescence staining of B16F10 tumor implants. Represen-
tative images of wild-type (WT) and R-Ras knockout (KO) tumor vessels are shown. See also Movies S1A and S1B.
(B) Pericyte coverage was quantified by calculating the percent fraction of vessel surface (CD31) area that overlapped with NG2 staining in the 3D image of the
vessels to determine direct contact between the two cell types. *p = 0.001, ± SEM.
(C and D) A 3D analysis of collagen IV coverage. CD31, red; collagen IV, green. *p = 4 3 1013.
(E) Double staining of Lewis lung carcinoma cells (LLC) tumors for CD31 (red) and VE-cadherin (green).
(F) CD31-staining of LLC and B16F10 tumor sections.
Scale bars, 100 mm (A, C, F), 50 mm (E).
(G and H) The perimeter and thickness of the endothelium (assessed by average CD31+ area per vessel) of tumor vessels were increased in R-Ras KO mice,
reflecting the augmented vessel deformations. *p = 0.01, **p < 0.001, ***p < 1 3 104.
Cancer Cell
Normalization of Tumor Vasculature by R-Rasindicating abnormal permeability, extensive leakage of intrave-
nously administered fluorescein isothiocyanate (FITC)-dextran
was found in these tumors (Figures 3C and 3D). The increasedpermeability of the R-Ras-deficient tumor vessels is consistent
with the reduced immunoreactivity to VE-cadherin of these
vessels (Figure 1E), suggesting that the disruption of R-RasCancer Cell 22, 235–249, August 14, 2012 ª2012 Elsevier Inc. 237
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Figure 2. R-Ras Regulates Tumor Vessel Phenotype
(A) Immunostaining of B16F10 tumor implants for CD31 (red) and VEGFR2
(green). Yellow, double-stained area.
(B) The VEGFR2 expression status of the tumor vasculature was assessed by
the fraction of VEGFR2-expressing vessel area (VEGFR2+CD31+ double-
positive) as a percentage of the total vessel area (total CD31). Each dot
represents the average of several vessels found in a micrograph. Fifteen
micrographs were obtained randomly frommultiple tumor sections. Eight wild-
type and five R-Ras KO mice were examined. *p = 1 3 105, ± SEM.
(C) A similar analysis with av integrin staining as a marker for angiogenic
vessels. Scale bar, 100 mm. **p = 2 3 1011.
See also Figure S1.
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Normalization of Tumor Vasculature by R-Rasdestabilizes endothelial adherent junctions of tumor vessels
increasing their permeability. Supporting the role of R-Ras in
endothelial integrity, ultrastructural analysis of the tumor vessels
revealed significantly increased presence of disrupted endothe-
lial cell-cell junctions in the R-Ras knockout mice, causing
spatial gaps between adjacent endothelial cells (Figure 3E).
Disruption of endothelial adherens junctions allows increased
penetration of tumor cells into the circulation (Weis et al., 2004).
Pericyte coverage of tumor vessels is also critical for limiting
blood-borne metastasis (Gerhardt and Semb, 2008). In our
study, tumor cells were rarely detected by PCR in the peripheral
blood of control mice bearing subcutaneous tumors. In contrast,
circulating tumor cells were readily detectable in the R-Ras
knockout mice bearing primary tumors of similar sizes, suggest-
ing that significantly increased number of tumor cells escaped
into the blood circulation in the knockout mice (Table S1). This
finding is consistent with the impaired endothelial barrier func-
tion and poor pericyte support of the R-Ras-deficient tumor
vasculature. Interestingly, we found a 4-fold increase in meta-238 Cancer Cell 22, 235–249, August 14, 2012 ª2012 Elsevier Inc.static foci counts in the lungs of knockout mice after tail vein
injection of tumor cells, suggesting that R-Ras may also regulate
the penetration of circulating tumor cells or tumor establishment
at secondary target tissues (Figure S2A).
We next determined the efficiency of blood perfusion through
the tumor vasculature by intravenously injecting biotin-labeled
tomato lectin, which highlights vessel lumens. Vessel perfusion
was markedly reduced in tumors growing in R-Ras knockout
mice compared to tumors in wild-type mice (Figures 3F, 3G,
and S2B). Furthermore, a contrast-enhanced ultrasonography
study showed delayed time to peak intensity of the contrast
perfusion in tumors in the knockout mice (Figures 3H and 3I),
an observation consistent with more irregular and deformed
vascular structure (Kersting et al., 2009). The reduced tumor
vessel perfusion coincided with elevated levels of tumor hypoxia
in R-Ras knockout mice (Figure 3J) despite a significant increase
in the vessel density in these tumors (Figure 3K). In addition, the
tumor size was not increased in R-Ras knockout mice despite
the increased vascularization (Figure 3L). These observations
indicate that the new vessels are immature to an extent that
renders them functionally defective. Importantly, in wild-type
mice, R-Ras was expressed at a 10-fold higher level by the
blood-perfused tumor vessel population than the nonperfused,
nonfunctional vessels (Figures 3M and 3N). A correlation
between increased R-Ras expression and vessel perfusion
was also found in human prostate tumor xenografts grown in
nude mice (Figure S2C). Thus, R-Ras expression is associated
with better blood flow in tumors, further reinforcing the link
between R-Ras expression and tumor vessel functions.
Since poor vascular function in tumors could lessen the
effectiveness of radiation treatments, we tested how R-Ras
deficiency affects the efficacy of local irradiation to the subcuta-
neous Lewis lung carcinoma tumor implants. In the wild-type
control group, a single dose of irradiation (12 Gy) resulted in
59% tumor volume reduction compared with the volume of
untreated group at 7 days post irradiation. In comparison, only
41% reduction was observed in the R-Ras knockout mice (Fig-
ure 3O). A similar decrease in the treatment effect was demon-
strated by in vivo bioluminescence intensity measurement,
which quantifies the amount of live tumor cell mass (Figures 3P
and 3R). Accordingly, the tumor growth delay by irradiation
was reduced in R-Ras knockout mice compared with wild-type
mice (Figure 3Q). These results indicate that R-Ras deficiency
negatively affects the effectiveness of radiotherapy. This finding
was consistent with the poor vessel function and elevated
hypoxia level in tumors of the R-Ras knockout mice (Figures
3A–3J).
Next, we examined the effect of VEGF blockade on R-Ras-
deficient tumor vessels. A single dose DC101 (anti-VEGFR2)
antibody treatment resulted in 50% reduction in the tumor vessel
density in the knockout mice while the same treatment had
minimal effect in wild-type mice at 3 days post treatment (Fig-
ure S2D). Because R-Ras deficiency exacerbates immaturity of
tumor vessels (Figures 1, 2, and S1), our result is consistent
with the previous findings indicating that immature vessels are
vulnerable to VEGF blockade (Benjamin et al., 1999). At the
dosage and treatment schedule we used, DC101 had little effect
on the growth of Lewis lung carcinoma tumors in wild-type or
R-Ras knockout mice (Figure S2E).
Cancer Cell
Normalization of Tumor Vasculature by R-RasR-Ras Is Downregulated in Human Tumor Vasculature
In mice, R-Ras is highly expressed in mature functional vessels
of normal tissues while it is downregulated to a level undetect-
able by immunofluorescence in the majority of tumor vessels
(Komatsu and Ruoslahti, 2005), except for the blood-perfused
functional vessels (Figures 3M and 3N). Notably, significant
downregulation of R-Ras was also observed in tumor vessels
in themajority of human breast cancers we examined, compared
with blood vessels in normal breast tissue (Figures 4A and 4B;
Table S2). This result corroborates the previous finding in gene
expression profiling study, which revealed significantly reduced
R-Ras mRNA level in the endothelium of human breast carci-
noma compared with the normal counterpart (Allinen et al.,
2004). Thus, R-Ras downregulation in tumor vasculature is found
in both mice and humans supporting the hypothesis that R-Ras
expression is chronically reduced in tumor vasculature contrib-
uting to immaturity and poor functionality of these vessels.
Upregulation of R-Ras Signaling Leads to Normalization
of Pathologically Regenerating Blood Vessels
The above observations prompted us to examine whether
restoring R-Ras signaling to pathologically regenerating blood
vessels will promote vessel maturation and improve structure
and functions of the defective vessels. For this purpose, lenti-
virus carrying activated R-Ras (R-Ras38V) or mock control virus
was injected into pre-implanted, VEGF-containing Matrigel
plugs that have developed angiogenic vessels in this tumor-
like environment in R-Ras knockout mice (Figure S3A). Following
forced expression of R-Ras38V (Figure S3B), the pericyte-endo-
thelial cell association of the newly formed microvessels in the
R-Ras knockout mice increased to a level comparable to that
in wild-type animals (Figures 4C and 4D). This effect was accom-
panied by reduced vessel dilation and thickness of the endothe-
lium, minimizing the deformation of the VEGF-induced vessels in
Matrigel (Figures 4E and 4F). Concomitantly, the efficiency of
blood perfusion improved by 74% in the R-Ras knockout vessels
that were successfully transduced with R-Ras38V compared
with non-transduced vessels within the same Matrigel plugs
(Figures 4G and 4H). Thus, the in vivo upregulation of R-Ras
signaling reverses the vessel phenotype and restores vessel
function in the pathologically developing vasculature.
Role of Endothelial R-Ras in Controlling Vessel
Sprouting and Maturation
R-Ras is expressed in both the endothelium and mural cells
(smooth muscle cells and pericytes). To determine the endothe-
lial cell-specific contribution of R-Ras, we used a technique that
combines lentivirus-mediated in vivo gene transduction and
Tie-2 promoter-driven gene expression. In this model, VEGF-
containing Matrigel was implanted into Tie2-rtTA mice, which
express reverse transactivator in an endothelial cell-specific
manner (Bao et al., 2010). Lentivirus carrying a vector for reverse
transactivator-dependent expression of activated R-Ras (pLVX-
Tight-Puro/R-Ras38V) was then injected into the pre-implanted
Matrigel plugs that were developing new vessels in response
to VEGF (Figure 5A). The mice received doxycycline daily to
induce the expression of R-Ras38V in a Tie2-rtTA-dependent
manner (Figures S4A and S4B). In this study, Dox-treated
(Dox+) mice showed significantly reduced vessel density in theMatrigel plugs compared with the plugs of Dox- animals demon-
strating a strong inhibitory activity of endothelial R-Ras against
vessel sprouting induced by VEGF (Figure 5B). Doxycycline itself
did not have any noticeable effect on the neovascularization in
the control mice without R-Ras38V virus infection (data not
shown). Importantly, the vessels developed in Matrigel were
significantly better perfused in Dox+mice than in Dox- mice, indi-
cating improved circulation in these vessels following R-Ras38V
induction (Figure 5C). Furthermore, pericyte coverage of these
vessels was also improved upon R-Ras38V induction in the
endothelium (Figures 5D and 5E). Because Matrigel itself
contains large amount of matrix components, it was not possible
to do specific immunostaining to assess basement membrane
coverage of these vessels; however, we observed enhanced
extracellular matrix depositions by cultured endothelial cells
upon R-Ras38V expression supporting a role of R-Ras in base-
ment membrane formation (Figure S4C). These observations
demonstrate an important activity of endothelial R-Ras,
promoting the formation of functional vessels after VEGF induc-
tion while inhibiting further vessel sprouting.
Role of R-Ras in Pericytes for Enhancing Vessel Integrity
We next used an ex vivo gene manipulation/cell transplantation
approach to determine the role of R-Ras signaling in pericytes
in vivo. Microvascular pericytes were isolated from wild-type
neonatal mouse brain (Wu et al., 2003) (Figures S4D–S4F) and
transduced ex vivo with cDNA for activated R-Ras (R-Ras38V)
or dominant negative R-Ras (R-Ras43N). R-Ras knockout mice
typically exhibit extensive hemorrhage in Matrigel plugs during
VEGF-induced angiogenesis (Figure 5F). However, implantation
of pericytes, which were ex vivo-transduced with activated
R-Ras, significantly prevented blood leakage in the plugs im-
planted into R-Ras knockout mice (Figure 5G). Histological
analysis of the plugs revealed association of the implanted peri-
cytes (green) with the tips of newly formed R-Ras-deficient
vessels (red) (Figure 5H). Pericytes transducedwith the dominant
negative R-Ras43N failed to show this effect, and the implanted
pericytes were mostly unassociated with the vessels (Figure 5H).
These findings are consistent with the fact that pericyte associa-
tion with endothelium is crucial for vessel integrity (Lindahl et al.,
1997; McDonald and Choyke, 2003). Thus, R-Ras activity in peri-
cytes alone can significantly contribute to the vessel maturation
process independently from endothelial R-Ras signaling.
However, R-Ras38V expression in the transplanted pericytes
was not very effective at improving blood circulation in the plugs
as measured by lectin perfusion (Figure S4G). This result
suggests that R-Ras signaling in pericytes contributes to vessel
maturation by promoting pericyte-endothelial cell interaction
thereby improving vessel integrity (reducing permeability),
whereas endothelial R-Ras is necessary to significantly improve
blood perfusion in VEGF-induced vessels (Figure 5C). Collec-
tively, our results demonstrate that R-Ras activity in endothelial
cells and in pericytes individually contribute to maturation and
normalization of pathologically regenerating blood vessels.
R-Ras Does Not Affect PHD2 or HIF-2 Levels during
Hypoxia
A recent study by Mazzone et al. showed that haplodeficiency of
the oxygen-sensing prolyl hydroxylase domain protein 2 (PHD2)Cancer Cell 22, 235–249, August 14, 2012 ª2012 Elsevier Inc. 239
Figure 3. R-Ras Deficiency Diminishes Tumor Vessel Function
(A–D) Analyses of vessel leakiness. Fibrinogen and CD31 staining for plasma leakage in B16F10 tumors (A). To quantify the level of plasma leakage and stan-
dardize it for tumor vessel area, the ratio of fibrinogen (fibrin)-stained area to CD31 area was determined and is presented as relative values (B). *p = 0.035, ± SEM.
Dextran-FITC was injected i.v. into mice bearing Lewis lung carcinoma (LLC) tumors (C). The fluorescence intensity of extravasated FITC in the tumors was
standardized for the perfused vessel counts to assess vessel permeability (D). *p = 0.002.
(E) Ultrastructure of tumor vessels by scanning electron microscopy. The R-Ras knockout (KO) tumor endothelium shows significant special gaps at the cell-cell
junctions (arrowheads). Arrow, a red blood cell extravasating between the cellular gap. Scale bar, 2 mm.
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Normalization of Tumor Vasculature by R-Rasleads to normalization of tumor vasculature through stabilization
of endothelial HIF-2a and a consequent upregulation of soluble
VEGFR1 and VE-cadherin expression in endothelial cells (Maz-
zone et al., 2009). The effect of PHD2 haplodeficiency and
HIF-2a stabilization exemplifies the significance of oxygen
sensing by endothelial cells for vessel integrity (Coulon et al.,
2010). We examined a potential role of R-Ras in regulating the
levels of these oxygen sensors. The expression of R-Ras38V
did not affect the levels of PHD2 or HIF-2a in cultured endothelial
cells in hypoxia or normoxia (Figure S5A). Likewise, downregula-
tion of endogenous R-Ras by shRNA knockdown had no effect
on the levels of these proteins (Figure S5B). These data do not
support the idea that R-Ras modulates PHD2/HIF-2 pathway
or that the vessel normalization effect of R-Ras is mediated via
HIF-2a stabilization. In addition, the expression of endogenous
R-Ras was not affected by hypoxia either in endothelial cells or
in pericytes (Figure S5C).
In vivo, we did not find any evidence to suggest that HIF-2a
level is decreased in the tumor vessels in R-Ras knockout
mice compared with wild-type control (Figure S5D). Further-
more, unlike the PHD2/HIF-2 model (Mazzone et al., 2009), the
expression levels of HIF-2 target genes, Cdh5 (VE-cadherin)
and Flt1 (VEGFR1), were not increased (Figure S5E) concurrently
with the vascular normalization promoted by endothelial R-Ras
in the doxycycline-inducible model (Figures 5A–5E). These
observations strongly suggest that R-Ras is not involved in
oxygen-sensing mechanisms of vessel regulations mediated
by the PHD2/HIF-2 pathway.
R-Ras Enhances Endothelial Barrier Function via
Suppression of VE-Cadherin Internalization
One possible mechanism of R-Ras-induced vessel normaliza-
tion is stabilization of endothelial adherens junctions via stabili-
zation of VE-cadherin. VE-cadherin is essential for the integrity
of blood vessel wall and for the regulation of vessel permeability
(Fukuhara et al., 2005). We observed disruption of endothelial
cell-cell junction (Figure 3E), elevated plasma leakage (Figures
3A–3D), and reduced VE-cadherin immunostaining of the tumor
vessels in R-Ras knockout mice (Figure 1E). Therefore, we next
examined the effect of R-Ras signaling on VE-cadherin.
In confluent endothelial cell cultures, R-Ras38V expression
induced marked accumulation of VE-cadherin and b-catenin at(F andG) Blood perfusion efficiency. Lectin perfusion and CD31 staining of B16F1
lectin+CD31+ double-positive area/total CD31+ area was determined to assess p
(H and I) Study of tumor vessel perfusion by contrast-enhanced ultrasound ima
microbubble contrast agent (H). Delayed time-to-peak-intensity in KO mice indic
(J) Analysis of tumor hypoxia. The ratio of the hypoxic area/total area of the tumor
Hypoxyprobe staining of LLC tumors is shown. *p = 0.03, **p = 0.003.
(K) Number of tumor vessels per unit area (vessel density) is presented relative t
(L) Growth of LLC and B16F10 tumors.
(M and N) Analysis of R-Ras expression in wild-type vessels. Sections of lecti
vessels were classified as lectin-perfused and non-perfused vessels, and the leve
*p = 7 3 104.
(O–R) Effect of radiotherapy. (O) The percent reduction in the tumor volume (as c
irradiation of LLC tumors (O). **p < 0.01 (P) Percent inhibition of tumor growth w
nescence intensity. *p = 0.02. (Q) Tumor growth delay as defined by delay in tumor
time (in days) is presented. **p < 0.01. (R) Bioluminescence imaging of Luc2-transf
tumors on the left thigh did not. WT, wild-type; KO, R-Ras KO mice.
Scale bars, 100 mm (A, C, F, and M), 200 mm (J). See also Figure S2 and Table Sthe cell-to-cell interface producing prominent and continuous
barrier walls of the adherens junctions (Figures 6A and 6B).
Despite this effect, the total expression level of neither VE-cad-
herin nor b-catenin protein in the cell was altered by activated
or dominant negative R-Ras (Figure 6C). In vivo, the VE-cadherin
immunofluorescence intensity was diminished in R-Ras-defi-
cient tumor vasculature (Figure 1E) although the VE-cadherin
protein level was unaltered (Figure S5F). This may be because
the detectable fluorescence signal declines with the loss of
VE-cadherin clustering at the cell-cell junctions. Therefore, we
hypothesized that R-Ras signaling may affect the localization
of VE-cadherin rather than regulating its gene expression.
VEGF stimulation of endothelial cells induces internalization of
VE-cadherin (Gavard and Gutkind, 2006). VE-cadherin localiza-
tion upon VEGF stimulation was analyzed using a monoclonal
antibody that recognizes the extracellular domain of VE-cadherin
(Figure 6D). The antibody displayed cell surface staining of
VE-cadherin that is sensitive to a mild acid wash. The acid-resis-
tant vesicular staining pattern represented the intracellular
vesicles containing VE-cadherin molecules that are internalized
(endocytosed) upon VEGF stimulation (Gavard and Gutkind,
2006). This analysis showed that R-Ras38V expression signifi-
cantly reduces the internalization of VE-cadherin (Figures 6D–
6F and S5G), causing an accumulation of VE-cadherin at the
cell-cell junctions despite the VEGF stimulation. The R-Ras43N
expression (Figures 6E and 6F) or knockdown of endogenous
R-Ras (Figure S5H) showed an opposite effect, increasing
VE-cadherin internalization during VEGF stimulation.
It has been shown that the phosphorylation of VE-cadherin at
Ser 665 in the cytoplasmic domain promotes VE-cadherin inter-
nalization upon VEGF stimulation (Gavard and Gutkind, 2006).
Interestingly, we found that this serine phosphorylation was
reduced by R-Ras38V expression almost to the level of the
non-stimulated control during VEGF stimulation (Figure 6G).
Thus, the reduction of Ser 665 phosphorylation observed here
was consistent with the reduction of VE-cadherin internalization
by R-Ras (Figures 6D–6F). The other VE-cadherin phosphoryla-
tion sites important for adherens junction disruption and
endothelial permeability, Tyr 658 (Dejana et al., 2008) and Tyr
731 (Allingham et al., 2007) were unaffected by R-Ras (Figure 6H)
or R-Ras knockdown (data not shown) during VEGF-stimulation.
Consistent with the role of R-Ras in VE-cadherin regulation and0 tumor sections (F). Yellow color indicates double-stained vessel area. Percent
erfusion efficiency of tumor vasculature (G). **p = 2 3 104.
ging. Examples of raw contrast kinetics acquired after bolus i.v. injection of
ating poor perfusion efficiency (I). **p = 0.02.
section was determined and presented as relative values. Representative anti-
o the control group. *p < 0.05.
n-perfused tumors were stained for CD31, lectin, and R-Ras (M). The tumor
l of R-Ras expression was determined for individual vessels in each group (N).
ompared with untreated tumors) was determined at 7 days after a local 12 Gy
as also assessed by bioluminescence tumor imaging at day 7. BLI, biolumi-
volume quadrupling time as a result of irradiation treatment. The average delay
ected LLC tumors. Tumors on the right thigh received 12Gy irradiation, whereas
1.
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Figure 4. R-Ras Promotes Normalization of VEGF-Induced Pathologically Regenerating Vasculature
(A andB) R-Ras is downregulated in human tumor vasculature. The level of R-Ras expression in tumor vessels was analyzed in a human breast cancer tissue array
by immunostaining for R-Ras and CD31 (A). Dot plot representation of A (B). **p = 0.004. See also Table S2.
(C–H) R-Ras signaling improves structure and function of VEGF-induced vessels. VEGF-induced angiogenic vessels developed in Matrigel plugs were trans-
duced in vivo with R-Ras38V or control lentivirus. Six days later, pericyte association with the endothelium was determined (C) by NG2 and CD31 immunoflu-
orescence (D). The data are presented as relative values. (E–H) The vessels in the R-Ras38V virus-infected plugs were classified as R-Ras-positive (successfully
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strongly suppressed the permeability of endothelial monolayer
(Figure 6I). R-Ras knockdown had an opposite effect (Figure S5I).
These results substantiated the in vivo observations of increased
tumor vessel permeability in R-Ras knockout mice (Figures 3A–
3D). Furthermore, the in vivo transduction of R-Ras38V en-
hanced VE-cadherin immunostaining at the endothelial cell-cell
junctions of angiogenic sprouts induced by VEGF in R-Ras
knockout mice (Figures 6J and 6K), supporting the importance
of R-Ras in the integrity of tumor vessels. Taken together,
R-Ras plays a crucial role in reinforcing the VE-cadherin-depen-
dent endothelial adherens junctions while counterbalancing the
effect of VEGF stimulation in the tumor microenvironment.
R-Ras Activation in Pericytes Induces Normal
Capillary-like Vessel Morphogenesis
The physical interaction of pericytes with endothelial cells is
essential to vessel maturation and functions. Our in vivo studies
showed that R-Ras activity in pericytes promotes the pericyte-
endothelial cell interaction in regenerating vessels (Figure 5H).
To recapitulate this phenomenon in vitro and to further analyze
the relative contribution of the pericyte-expressed R-Ras to
vessel formation, we used an endothelial cell/pericyte 3D cocul-
ture that reconstitutes microvessels in Matrigel (Figures 7A–7E).
In this model, the coculture produced networks of vessel-like,
elongated endothelial structures with associated pericytes
(Figures 7A–7C). In the control coculture with mock-transduced
pericytes, the pericytes were found loosely or incompletely
associated with endothelial cells and appeared to be activated,
invasive, and irregularly extended out from the main stalk of
the vessels with long cytoplasmic processes (Figure 7A). These
features are strikingly similar to the abnormalities in pericytes
associated with tumor blood vessels (McDonald and Choyke,
2003). In contrast, such tumor-associated characteristics of
pericytes were significantly diminished by the expression of
activated R-Ras in pericytes (Figure 7B). Instead, most pericytes
were flattened, widely spread, or extended with long thin
processes over the surface of the vessel-like structures, and
were intimately associated with endothelial cells, as seen for
the pericytes of normal capillary or microvessels. The dominant
negative R-Ras did not show this effect (Figure 7C). The number
of pericyte projections was also decreased by the activated
R-Ras but increased by the dominant negative R-Ras signifying
pericyte stabilization by R-Ras activity (Figures 7D and 7E). The
ability of R-Ras to suppress invasive nature of pericytes was
substantiated by the observation that R-Ras38V expression
but not R-Ras43N or R-Ras knockdown strongly suppressed
dynamic membrane projection/retraction activities (Figures 7F–
7H and Figure S6A), motility on the Matrigel-coated surface (Fig-
ure 7I and Figure S6B), and invasion through Matrigel (Figure 7J)
of the pericytes. These effects were also observed in culturedtransduced) or negative (non-transduced) vessels. The in vivo R-Ras transduction
mice (E). The thickness of the endothelium (assessed by average CD31+ are
The histological sections of Matrigel implants in R-Ras KO mice, which recei
to determine the blood perfusion of the vessels (G). Blood perfusion efficiency wa
*p < 0.05, ***p < 1 3 103, ± SEM. Scale bars, 100 mm.
See also Figure S3.endothelial cells (Figures S6C–S6E) but not in C2C12 myoblasts
or NIH 3T3 fibroblasts demonstrating cell type-dependent effect
of R-Ras (Figures S6F and S6G).
Pericytes interact closely with endothelial cells by adhering to
the endothelial basement membrane that is shared by both cell
types (Armulik et al., 2005). The ability of R-Ras to promote inti-
mate association of pericytes with endothelial cells observed
in vivo (Figure 5H) and in vitro (Figure 7B) may be attributable
to enhancement of integrin-mediated cell adhesion to the extra-
cellular matrix (ECM) (Kinbara et al., 2003; Zhang et al., 1996).
R-Ras38V expression in pericytes resulted in enhanced pericyte
adhesion to endothelial basement membrane components,
collagen IV and laminin (Figure S6H). In the control pericytes
with mock-transduction or shRNA knockdown of endogenous
R-Ras, the presence of focal adhesion complexes was limited
to the leading edge of migrating cells or protruding membranes
(Figure 7K). In contrast, R-Ras38V expression resulted in
assembly of numerous focal adhesion complexes throughout
the cell perimeter, facilitating the flattening and wide spreading
of cell membrane over the ECM-coated surface (Figure 7K).
These results demonstrated the profound effect of R-Ras on
pericyte-ECM interaction and support the importance of peri-
cyte-expressed R-Ras for pericyte association with nascent
microvessels and the stabilization of these vessels as observed
in vivo (Figure 5H).
DISCUSSION
Studies by others have elucidated the importance of early-acting
signaling pathways for vessel maturation, such as angiopoietin-
1/Tie-2 and platelet-derived growth factor (Andrae et al., 2008;
Thomas and Augustin, 2009). However, it has been unclear
what directs the maturation process further to establish func-
tional vessels during tumor angiogenesis. This is an important
question because tumor progression and the efficacy of thera-
peutic regimens both depend on blood circulation in the tumors.
In this study, we showed that R-Ras promotes the maturation of
blood vessels in the tumor microenvironment and that, through
this activity, R-Ras governs integrity and functionality of tumor
vasculature (Figure 8).
Malformation and malfunction of tumor vessels are exacer-
bated by genetic disruption of R-Ras. Increased tumor cell pene-
tration into the circulation in R-Ras knockout mice also supports
the role of R-Ras in controlling the permeability of tumor vessels.
The reduced perfusion of tumor vessels was consistent with
elevated tumor hypoxia, which, in turn, led to reduced efficacy
of radiotherapy in R-Ras knockout mice. In addition, R-Ras
knockout tumor vessels were sensitized to VEGF blockade, as
expected from exacerbated immaturity of these vessels
(Benjamin et al., 1999). However, the antitumor effect of
DC101 was not enhanced in the knockout mice. A possiblereduced the vessel perimeter (reduced vessel dilation) in R-Ras knockout (KO)
a per vessel) was also reduced in the KO mice by R-Ras transduction (F).
ved control or R-Ras38V virus, were stained for perfused lectin, and CD31
s compared between the R-Ras-transduced and non-transduced vessels (H).
Cancer Cell 22, 235–249, August 14, 2012 ª2012 Elsevier Inc. 243
Dox treatment
Transcription
rtTADox
Day 0
Matrigel
+VEGF
implantation
Infection with 
inducible R-Ras38V
lentivirus
Day 5 TRE CMV R-Ras38VDay 11
Lectin perfusion
C Dox-
se
l d
en
si
ty
1.0
1.5
*
1.5
2.0
2.5
n
pe
rf
us
io
n
*
30
40
er
ag
e 
(%
)
*
NG2/CD31
Dox+
Dox
R
el
at
iv
e 
ve
ss
0.0
0.5
- +
0.0
0.5
1.0
R
el
at
iv
e 
le
ct
i
- +
Dox
0
10
20
P
er
ic
yt
e 
co
ve
Dox
- +
WT
KO
Recipient 
mice
Matrigel plugs 
with extensive 
blood leakage
WT 22%      (2/9)
A
B D E
F
G H
KO 83%  (10/12)
 sgulplegirtaMetycireP
with extensive 
blood leakage
Injected pericyte/CD31
Activated R-Ras 33.3%    (3/9)
Dominant negative R-Ras 88.8%    (8/9)
Mock transduction 50.0%    (4/8)
Figure 5. The Effect of Cell-Type Specific Upregulation of R-Ras on
Vessel Maturation and Functions
(A–E) The effect of endothelial specific R-Ras. A timetable of Matrigel
implantation in Tie2-rtTA transgenic mice, lentivirus infection, R-Ras38V
induction by doxycycline (Dox), and lectin i.v. perfusion is shown (A). Vessel
density in the Matrigel plugs at Day 11 (B). Relative perfusion efficiency of i.v.
injected lectin at Day 11 (C). (D and E) Matrigel sections were stained for NG2
and CD31 (D), and pericyte coverage of the vessels was determined by image
analysis (E).
(F) VEGF-induced Matrigel angiogenesis produces extensively ‘‘bloody’’ plugs
in R-Ras knockout (KO) mice demonstrating enhanced leakiness of patho-
logically regenerating vessels in the absence of R-Ras.
(G and H) The effect of pericyte specific R-Ras. Fluorescently labeled, ex vivo-
transduced pericytes were implanted with VEGF-containing Matrigel into the
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mainly destroyed highly immature nonfunctional vessels, which
did not significantly contribute to tumor growth.
In contrast to the R-Ras gene disruption, the gain of function of
R-Ras improved the structure and perfusion of blood vessels
induced by VEGF in tumor ECM extract (Matrigel) implants.
Other cell types such as infiltrating macrophages and fibroblasts
may have also contributed to the observed effects. However, the
studies using endothelial cell-specific or pericyte-specific
expression of R-Ras gave insights into how R-Ras in each
vascular cell type contributes to the overall vessel formation
process. For instance, R-Ras activity in endothelial cells was
sufficient to inhibit VEGF-induced vessel outgrowth. This effect
coincided with improved pericyte coverage and enhanced blood
perfusion of newly formed vessels. These observations suggest
that endothelial R-Ras activity redirects nascent vessel forma-
tion from angiogenic process to maturation process. In contrast,
R-Ras activity in pericytes prevented severe leakiness of the
R-Ras knockout endothelium through facilitating pericyte asso-
ciation with the sprouting vessels. This result indicates that
R-Ras activity in pericytes alone can significantly contribute to
the vessel maturation process independently from endothelial
R-Ras. However, enhanced R-Ras signaling in pericytes was
not very effective at improving perfusion of the vessels to which
the pericytes are attached. Therefore, the role of pericyte R-Ras
in vessel maturation may be primarily to promote pericyte asso-
ciation with endothelial cells, thereby providing integrity to the
vessel structure and reducing permeability. The endothelial
R-Ras activity appears to be more effective in improving blood
perfusion of newly formed vessels. However, we cannot rule
out the possibility that the ex vivo R-Ras transduction and peri-
cyte transplantation model we used in this study may have not
been fully recapitulating the in vivo functions of R-Ras in peri-
cytes. A transgenic mouse model for pericyte-specific R-Ras
expression will be needed to clarify this point in future studies.
A recent study by Mazzone et al. demonstrated vascular
normalization phenomenon caused by PHD2 haplodeficiency
and consequential HIF-2 upregulation (Mazzone et al., 2009).
Our data did not support the PHD2/HIF-2-dependent endothe-
lial cell regulation as a mechanism by which R-Ras promotes
vascular normalization. In the study by Mazzone et al., haplode-
ficiency of PHD2 resulted in an elevated HIF-2a level in
endothelial cells during hypoxia, which led to HIF-2-driven upre-
gulation of VE-cadherin and soluble-VEGFR1 expressions in
endothelial cells. This cascade, in turn, led to vascular normal-
ization (Mazzone et al., 2009). In our study, constitutively
activated R-Ras did not affect VE-cadherin expression in endo-
thelial cells. Instead, it inhibited VE-cadherin internalization
induced by VEGF stimulation of endothelial cells. This resulted
in VE-cadherin accumulation at adherens junctions and stabili-
zation of the endothelial barrier. In our previous study of tran-
scriptional regulation of human RRAS gene, we did not findflank of R-Ras KO mice. Matrigel plugs were examined 7 days later (indicated
by dashed lines) (G). Histological analysis of the plugs (H). The ex vivo-
transduced, implanted pericytes were visualized by green fluorescence.
Microvessels were stained with CD31 (red). Scale bars, 100 mm (H), 50 mm (D).
*p < 0.05, ± SEM.
See also Figure S4.
Figure 6. R-Ras Stabilizes Endothelial Adherens Junctions and Improves Endothelial Barrier Function via Suppression of VE-Cadherin
Internalization
(A) R-Ras enhances adherens junction formation in EC monolayer. VE-cadherin (green) and b-catenin (red) staining of human umbilical vein endothelial cell
(HUVEC) monolayers transduced with R-Ras38V or control vector. Lower left panels and right panels are merged images of the double staining. Right panels
show higher magnification at cell-cell junctions.
(B) Surface plot of VE-cadherin and b-catenin immunofluorescence intensity shows marked accumulation of both proteins at the cell-cell interface upon
R-Ras38V expression. The immunoreactivity is shown with arbitrary unit.
(C) VE-cadherin and b-catenin immunoblotting of whole cell lysate. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is shown as a loading control.
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promoter region or the 50 upstream cis-regulatory sequences
(Xu and Komatsu, 2009). This suggests that, unlike many
hypoxia induced angiogenesis regulators, R-Ras expression is
not controlled by oxygen sensing mechanism involving HIFs.
Indeed, R-Ras expression level did not increase in endothelial
cells or pericytes under hypoxia. There is an additional impor-
tant difference between the vessel regulations by PHD2/HIF-2
and by R-Ras. PHD2 haplodeficiency does not affect vessel
density, area, or vessel dilation while it normalizes the endothe-
lial barrier and stability (Mazzone et al., 2009). In comparison,
R-Ras does normalize all of these vessel parameters while
halting angiogenic sprouting. Based on these observations,
we propose that the R-Ras-dependent mechanism is distinct
from the oxygen sensing mechanism of vascular normalization.
The chronic low-oxygen environment is a hallmark of solid
tumors, and the levels of HIF proteins are elevated in the cells
in the tumor microenvironment. Yet tumor vessels are chroni-
cally abnormal instead of being normalized. The observations
reported in this study suggest an alternative, oxygen sensing-
independent vascular normalization phenomenon.
This study also identified a cellular function of R-Ras:
enhancement of endothelial cell-cell adhesion via regulation of
VE-cadherin internalization induced by VEGF. R-Ras inhibits
VE-cadherin phosphorylation at Ser 665 residue that is critical
for the VE-cadherin internalization process upon VEGF stimula-
tion, suggesting the modulation of this site by R-Ras. Additional
mechanism(s) independent of Ser 665 may also be involved in
the R-Ras-mediated VE-cadherin regulation. Identification of
the signaling pathways for these regulations is an important
goal of future work that could further advance our understanding
in the vascular normalization process.
The upregulation of R-Ras activity in pericytes resulted in
enhanced pericyte adhesion to ECM and formation of focal
adhesion complexes around cell perimeter facilitating the flat-
tening and wide spreading of pericyte cell membrane over the
adhering surface. Consistent with this effect, the activated
R-Ras facilitated close association of pericytes with nascent
microvessel sprouts in vivo, and this phenomenon was recapit-
ulated in a 3D coculture system. These studies show that
R-Ras plays important roles in both pericytes and endothelial
cells. Thus, R-Ras in each cell type is vital to tumor vessel matu-
ration process.(D) Analysis of VEGF-induced VE-cadherin internalization. The monoclonal antibo
antibody incubation of the EC culture and stimulation with VEGF, the cell surface
wash (lower panels). The presence of internal acid-resistant vesicles stained with
red; nucleus, blue; arrows, BV6-stained vesicles containing internalized VE-cadh
(E) Dominant negative R-Ras43N enhances VE-cadherin internalization.
(F) VE-cadherin internalization was quantified by the percentage of the cells showin
stimulation condition (), statistical significance was not found between the con
(G) Phosphorylation of VE-cadherin S665 was analyzed in the lysate of VEGF-sti
(H) Phosphorylation of VE-cadherin Y658 and Y731 residues.
(I) The effect of R-Ras on the endothelial permeability was determined in HUVEC
cells was set as 100%.
(J) The in vivo transduction of R-Ras38V increased VE-cadherin immunoreac
Immunofluorescence showed accumulation of VE-cadherin at the endothelial ce
(K) Quantification of VE-cadherin immunoreactivity standardized with CD31 ar
***p < 0.001.
Scale bars, 20 mm (J), 25 mm (D), 50 mm (A, E). See also Figure S5.
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useful for normalizing tumor vasculature. In contrast to the VEGF
blockade, which only induces transient vascular normalization
with the narrow window of therapeutic opportunity (Carmeliet
and Jain, 2011b), the R-Ras effect is sustained. Also, unlike the
VEGF blockade, R-Ras does not cause subsequent destruction
of the newly formed vessels. Instead, R-Ras stabilizes these
vessels. This may be a significant advantage in improving drug
delivery to the tumors and inother situations inwhichstable, func-
tional vascularization is beneficial, for example, angiogenesis in
ischemic heart. R-Ras may also be useful as a biomarker for the
vessel maturity and functionality, for instance, to assess vessel
normalization, and for drug screens/validation. As maturation of
blood vessels is essential for the establishment of functional
vasculature in regenerating adult tissues, our findings suggest
the significance of R-Ras to a broad range of clinical challenges,
from cancer to therapeutic angiogenesis and tissue engineering.EXPERIMENTAL PROCEDURES
Analyses of Tumor Blood Vessels
All animal experimentswere performed in accordancewith protocols approved
by the institutional animal care and use committees of the Sanford-Burnham
Medical Research Institute (SBMRI) and the University of Alabama at Birming-
ham. TheR-Ras knockoutmouse line has been described previously (Komatsu
and Ruoslahti, 2005). The mice received subcutaneous implantations of 1 3
106 B16F10 mouse melanoma cells or Lewis lung carcinoma cells at the
flank, and the tumors were excised at days 10 and 14, respectively. The 3 3
106PPC-1 humanprostate tumor cells in 50%-dilutedMatrigelwere inoculated
subcutaneously at the flank of athymic nude mice. The tumors were excised
2 weeks later. Tumors were cryosectioned and tumor vessels were analyzed
by immunofluorescence (see Supplemental Information). Six to seven mice
per group were used, and vessels in several micrographs from each tumor
section were analyzed unless indicated otherwise.
In Vivo Gene Transfer
Matrigel (BD Bioscience; 0.5 ml) containing 60 ng/ml VEGF (R&D systems)
and 60 U/ml heparin (Sigma) was injected into the flanks of wild-type or
R-Ras knockout mice. Five days later, lentivirus carrying activated R-Ras
(R-Ras38V) or control vector was injected into the Matrigel plugs at 1 3 106
transduction unit. At 6 days post lentivirus inoculation, mice received intrave-
nous injection of biotinylated lycopersicon esculentum (tomato) lectin to
analyze vessel perfusion. Five to six mice per group were used. Matrigel plugs
were collected and the sections stained for CD31, NG2, R-Ras, and streptavi-
din to analyze the vessel structure, pericyte association, and perfusion
efficiency.dy (BV6) recognizes the extracellular domain of VE-cadherin (green). Following
membrane-bound BV6 antibodies (upper panels) were removed by a mild acid
the BV6 antibody indicates the internalization of VE-cadherin. Phalloidin (actin),
erin.
g internal acid-resistant vesicles. *p < 0.05, **p < 0.001, ± SEM. In the no-VEGF
trol, R-Ras38V, and R-Ras43N.
mulated endothelial cells (ECs) (100 ng/ml) using phospho-specific antibody.
monolayer cultures. BSA leakage through the culture insert membrane without
tivity of angiogenic sprouts in Matrigel plugs implanted in R-Ras KO mice.
ll-cell junctions upon R-Ras transgene expression (arrows).
ea was compared between R-Ras38V and mock transduced control plugs.
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Figure 7. R-Ras Regulates Pericytes in the In Vitro-Reconstituted Microvessels
(A and B) Fluorescently labeled pericytes (green) were transduced with R-Ras38V or control vector and, at 3 hr post transduction, they were plated together
with red-labeled endothelial cells (ECs) onto Matrigel at a 4:1 (EC: pericyte) ratio, cultured for 24 hr, and the resulting vessel-like structures were analyzed by
fluorescent microscopy. In the control cocultures (A), pericytes were loosely attached to the vessel-like EC structures (arrowhead) with cytoplasmic processes
(arrows). Upon R-Ras38V expression in pericytes, these abnormal characteristics were significantly diminished, and ECs and pericytes became tightly
associated (B).
(C) R-Ras43N expression in pericytes did not have this effect.
(D and E) The number of pericyte projections from the reconstituted microvessels was significantly decreased by R-Ras38V (D) but increased by R-Ras43N
expression (E).
(F) Time-laps video microscopy of pericytes on the Matrigel-coated two-dimensional (2D) surface shows membrane projection/retraction activities of the
pericytes. Arrows indicate dynamic membrane activities (orange, projections; blue, retractions).
(G and H) The fractions of projecting (red) and retracting (blue) membrane area versus total cell area (% area change) were determined between the time points
0 and 5 min. See also Figure S6.
(I) The mean velocity of pericyte motility was calculated from 20 hr-long time-lap observations in 2D culture.
(J) Pericyte invasion through Matrigel-coated filter membrane.
(K) Immunofluorescence of phospho-paxillin Y118 and phospho-FAK Y397 to highlight focal adhesions complexes (green) assembled throughout the cell
perimeter upon R-Ras38V expression. Scale bars, 50 mm. *p < 0.05, **p < 0.001, ± SEM.
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Figure 8. Regulation of Tumor Vessel Matu-
ration by R-Ras
Schematic summary of the consequences of
R-Ras disruption and upregulation in tumor blood
vessels. The disruption of R-Ras severely impairs
structural and functional maturation of tumor
vessels. These vessels exhibit the poorly pericyte-
supported ‘‘vulnerable’’ immature phenotype,
which highly expresses VEGFR2 and av integrins.
The structural abnormalities are associated with
extensive blood leakage, reduced blood perfusion,
and elevated hypoxia within tumors. In contrast,
upregulation of R-Ras signaling enhances pericyte
association and stabilizes VE-cadherin at the
endothelial adherens junctions, leading to
improved vessel structure and endothelial barrier
function with improved blood perfusion. Thus,
R-Ras signaling promotes normalization of patho-
logically regenerating blood vessels.
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of R-Ras
The Tie2-rtTA transgenic mouse line has been described previously (Bao et al.,
2010). Matrigel containing 60 ng/ml VEGF and 60 U/ml heparin was injected
into the flanks of Tie2-rtTA transgenicmice. Five days later, lentivirus harboring
pLVX-Tight-Puro/R-Ras38V expression vector was injected into the Matrigel
plugs at 106 transduction units. Doxycycline was administrated i.p. daily at
5 mg/kg from Day 5 to Day 10. At Day 11, mice were perfused with biotinylated
tomato lectin. Four mice per group were examined. To confirm the induction of
R-Ras38V, mRNA was isolated from the plugs, and RT-PCR was conducted
using a primer set for human R-Ras: 50-GACCCCACTATTGAGGACTCC-30
and 50-CTACAGGAGGACGCAGGG-30. RT-PCR for cyclophilin A was used
as control.
Pericyte Implantation into R-Ras Knockout Mice
Microvascular pericytes were isolated fromwild-type neonatal mouse brain (Wu
et al., 2003) and transduced ex vivo with R-Ras38V, R-Ras43N, or control lenti-
virus. These pericytes were fluorescently labeled with 8 mM CellTracker green
for 30 min, and 3 3 105 cells were implanted into the flank of R-Ras knockout
mice after mixed with 0.5 ml Matrigel containing VEGF and Heparin. Seven
days later, the Matrigel plugs were grossly examined for the extent of blood
leakage in the plugs. The association of the implanted pericytes (green-labeled)
with vessels was analyzed in histological sections by fluorescence microscopy.
Statistics
Statics were performed using the two-tailed Student’s t test to compare wild-
type with R-Ras knockout mice and the one-way ANOVAwith Tukey’s multiple
comparison test for in vitro experiment. Error bars represent SEM.
Additional Supplemental Experimental Procedures are available online in
the Supplemental Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes two movies, six figures, two tables, and
Supplemental Experimental Procedures and can be found with this article on-
line at http://dx.doi.org/10.1016/j.ccr.2012.06.013.
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